- Wegovy is FDA-approved with data from 4,500+ trial participants and 8 years of real-world use as semaglutide
- Common side effects are GI-related (nausea, diarrhea, constipation) and usually improve during titration
- The SELECT trial showed a 20% reduction in cardiovascular events — the first such finding for an anti-obesity drug
- Thyroid cancer risk has not been confirmed in humans despite the boxed warning from rodent studies
- Safety assessment should weigh medication risks against the well-established risks of untreated obesity
FDA approval history and regulatory context
Semaglutide has a well-documented regulatory history. Ozempic (semaglutide) was approved by the FDA in 2017 for type 2 diabetes management. Wegovy (semaglutide 2.4 mg) received FDA approval in June 2021 specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition.
The FDA approval of Wegovy was based on the STEP clinical trial program, which enrolled over 4,500 participants across four Phase 3 trials. This is a substantial evidence base — far larger than what is available for most weight loss interventions.
In March 2024, the FDA expanded Wegovy's indication to include reduction of cardiovascular risk in adults with established cardiovascular disease and either obesity or overweight, based on the SELECT trial results. This was the first anti-obesity medication to receive a cardiovascular risk reduction indication.
FDA approval requires manufacturers to demonstrate safety and efficacy through rigorous, multi-phase clinical trials with thousands of participants. Post-approval surveillance continues indefinitely. This is a fundamentally different standard than what compounded or off-label medications undergo.
Common side effects and their frequency
The most frequently reported side effects with Wegovy are gastrointestinal in nature. These typically occur during the dose escalation phase (first 16–20 weeks) and tend to improve as the body adjusts to the medication.
| Side effect | Wegovy (2.4 mg) | Placebo |
|---|---|---|
| Nausea | 44% | 16% |
| Diarrhea | 30% | 16% |
| Vomiting | 24% | 6% |
| Constipation | 24% | 11% |
| Abdominal pain | 20% | 11% |
| Headache | 14% | 12% |
| Fatigue | 11% | 6% |
| Dyspepsia (indigestion) | 9% | 4% |
| Dizziness | 8% | 6% |
| Injection site reactions | 3.2% | 2.6% |
In the STEP trials, 7% of participants discontinued Wegovy due to adverse events, compared to 3.1% on placebo. The vast majority of side effects were mild to moderate in severity and resolved without intervention.
The gradual dose titration used with Wegovy (starting at 0.25 mg and increasing every 4 weeks) is specifically designed to minimize these side effects. Patients who rush the titration or skip doses during escalation tend to experience more pronounced GI symptoms.
Thyroid cancer warning: what you should know
Wegovy carries a boxed warning about the risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). This warning is based on animal studies in which rodents given semaglutide developed thyroid tumors.
It is important to put this in context. Rodent thyroid C-cells respond differently to GLP-1 stimulation than human cells. To date, no causal link between semaglutide and thyroid cancer has been established in humans. Large epidemiological studies following millions of patients exposed to GLP-1 medications have not identified an increased risk of thyroid cancer.
Despite the reassuring human data, Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). If you have a history of thyroid cancer or thyroid nodules, discuss this thoroughly with your clinician before starting treatment.
Pancreatitis risk
Acute pancreatitis has been reported in patients taking GLP-1 medications, including semaglutide. In the STEP trials, the incidence was low (less than 0.5%) but higher than in the placebo group.
Patients should be aware of the symptoms of pancreatitis: severe, persistent abdominal pain that may radiate to the back, often accompanied by nausea and vomiting. If you experience these symptoms, contact your healthcare provider immediately. Treatment should be discontinued if pancreatitis is confirmed.
Risk factors for pancreatitis include a history of pancreatitis, gallstones, heavy alcohol use, and very high triglycerides. Your PEAK clinician evaluates these risk factors as part of your initial assessment.
Gallbladder events
Rapid weight loss from any cause increases the risk of gallstone formation and gallbladder-related events. In the STEP trials, gallbladder-related events (including cholelithiasis and cholecystitis) were reported in 2.6% of Wegovy patients versus 1.2% on placebo.
This risk is not unique to Wegovy — it occurs with any intervention that produces rapid or significant weight loss, including dietary programs and bariatric surgery. The risk appears proportional to the rate and magnitude of weight loss rather than the medication itself.
Patients with a history of gallbladder disease or gallstones should discuss this risk with their clinician. Symptoms to watch for include upper right abdominal pain, especially after eating, nausea, and pain radiating to the right shoulder.
SELECT trial: cardiovascular benefit
One of the most significant safety findings for semaglutide came from the SELECT trial, which studied cardiovascular outcomes in over 17,600 adults with overweight or obesity and established cardiovascular disease.
Semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (MACE) — a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke — by 20% compared to placebo over a median follow-up of 40 months.
The SELECT trial was the first to demonstrate that an anti-obesity medication can reduce cardiovascular events. This finding fundamentally changed the risk-benefit calculus for semaglutide, particularly in patients with existing heart disease. The FDA subsequently added cardiovascular risk reduction as an approved indication for Wegovy.
The cardiovascular benefit appeared to be at least partially independent of weight loss, suggesting that semaglutide has direct anti-inflammatory and vascular protective effects. This is an active area of ongoing research.
Mental health and suicidal ideation
In 2023, the European Medicines Agency (EMA) initiated a review of potential suicidal ideation and self-harm with GLP-1 medications following a small number of case reports. The FDA also evaluated this concern.
Both the EMA and FDA reviews found no causal link between GLP-1 medications and suicidal ideation or depression. Large observational studies involving millions of patients have not identified an increased risk. Some studies have actually suggested a potential protective effect on mental health outcomes.
However, any significant life change — including rapid weight loss — can affect mental health. Patients with a history of depression, anxiety, or disordered eating should maintain regular mental health follow-up during GLP-1 treatment. If you experience mood changes, tell your care team promptly.
Kidney considerations
GLP-1 medications can cause dehydration through reduced fluid intake (decreased appetite) and gastrointestinal fluid losses (nausea, vomiting, diarrhea). Dehydration can worsen existing kidney function impairment.
In the STEP trials, acute kidney injury was rare but was reported more frequently in patients who experienced significant GI side effects without adequate hydration. The FLOW trial, published in 2024, actually demonstrated that semaglutide reduced the risk of kidney disease progression in patients with type 2 diabetes and chronic kidney disease.
Patients with existing kidney disease should be monitored more closely, and hydration should be emphasized, particularly during the dose titration phase when GI side effects are most common.
Who should not take Wegovy
Wegovy is contraindicated in certain populations. Your clinician will screen for these during your initial evaluation.
- Personal or family history of MTC or MEN 2 — due to the thyroid C-cell tumor warning
- Known hypersensitivity to semaglutide — allergic reactions, though rare, require immediate discontinuation
- Pregnancy or planned pregnancy — Wegovy should be stopped at least 2 months before conception due to the long half-life
- Current or recent pancreatitis — until fully resolved and risk factors addressed
- Severe gastroparesis — semaglutide slows gastric emptying and may worsen this condition
Certain conditions require cautious use with close monitoring rather than absolute contraindication, including a history of gallbladder disease, mild-to-moderate kidney impairment, diabetic retinopathy, and concurrent use of insulin or sulfonylureas (due to hypoglycemia risk).
Long-term safety: what we know and what we are still learning
Semaglutide has been available for clinical use since 2017 (as Ozempic for diabetes) and since 2021 (as Wegovy for weight management). This provides approximately 8 years of real-world safety data for semaglutide as a molecule, though the higher 2.4 mg dose has a shorter track record.
Post-marketing surveillance, which involves monitoring adverse events reported after FDA approval, has not identified any new safety signals beyond what was observed in clinical trials. This is reassuring but does not eliminate the possibility of rare, long-term effects that may emerge with broader and longer-duration use.
Multiple long-term studies are currently underway, including trials examining semaglutide's effects on heart failure, kidney disease, fatty liver disease, and overall mortality. These studies will continue to refine our understanding of the long-term safety profile over the coming years.
It is worth noting that the risks of untreated obesity are well-established and substantial: increased risk of heart disease, stroke, type 2 diabetes, certain cancers, sleep apnea, joint disease, and reduced life expectancy. Any medication safety assessment should be weighed against these known risks of the condition it treats.
The risk-benefit framework
No medication is without risk. The question is not whether Wegovy has risks but whether the benefits outweigh those risks for you, given your specific health situation.
The most important safety question is not whether a medication has risks, but whether the risks of treatment are outweighed by the risks of not treating.
For most patients with obesity or overweight with weight-related health conditions, the evidence strongly favors treatment. The STEP trials demonstrated significant weight loss, the SELECT trial demonstrated cardiovascular risk reduction, and real-world data confirms a manageable safety profile.
At PEAK, the safety conversation is not a formality — it is an ongoing dialogue. Before prescribing, we evaluate your complete health history, screen for contraindications, and discuss expected side effects. After starting treatment, we monitor your progress, labs, and side effects at regular intervals.
If you have concerns about Wegovy's safety profile, the best step is to discuss them with a clinician who can evaluate your specific situation rather than relying on general information alone.
